A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)
Latest Information Update: 23 Oct 2024
Price :
$35 *
At a glance
- Drugs Zanidatamab (Primary)
- Indications Carcinoma; Endometrial cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms ZW25-IST-2
- 04 Jun 2024 Results(n=701) discussing Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 01 Mar 2024 Planned End Date changed from 12 Feb 2024 to 12 Feb 2025.